Abstract
There is a high incidence of acute kidney injury with COVID-19 infections. The etiologies of acute kidney injury could be ischemic acute tubular necrosis or a complex process of complement activation leading to thrombotic microangiopathy. We present a case of 32-year-old Hispanic male with a history of heart transplant, admitted with COVID-19 and atypical hemolytic uremic syndrome, which was successfully treated with Eculizumab.
Keywords: Acute kidney injury; COVID-19; Eculizumab; Thrombotic microangiopathy.
All Keywords
【저자키워드】 COVID-19, eculizumab, Acute kidney injury, Thrombotic microangiopathy., 【초록키워드】 complement, kidney, infections, male, incidence, etiology, Hispanic, thrombotic microangiopathy, Atypical, acute tubular necrosis, Activation, complex, thrombotic, uremic syndrome, treated, with COVID-19, 【제목키워드】 therapy, Atypical, uremic syndrome,
【저자키워드】 COVID-19, eculizumab, Acute kidney injury, Thrombotic microangiopathy., 【초록키워드】 complement, kidney, infections, male, incidence, etiology, Hispanic, thrombotic microangiopathy, Atypical, acute tubular necrosis, Activation, complex, thrombotic, uremic syndrome, treated, with COVID-19, 【제목키워드】 therapy, Atypical, uremic syndrome,
{{{ 추상적인 }}}
COVID-19 감염으로 인한 급성 신장 손상의 발생률이 높습니다. 급성 신장 손상의 원인은 허혈성 급성 세뇨관 괴사 또는 혈전성 미세혈관병증으로 이어지는 보체 활성화의 복잡한 과정일 수 있습니다. 심장 이식 이력이 있는 32세 히스패닉 남성으로 COVID-19 및 비정형 용혈성 요독 증후군으로 입원하여 Eculizumab으로 성공적으로 치료된 증례를 제시합니다.
{{ 키워드: }} 급성 신장 손상; 코로나바이러스감염증-19 : 코로나19; 에쿨리주맙; 혈전성 미세혈관병증.